1
EPISODE · Apr 22, 2026 · 16 MIN
What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path
from 1nessAgency Insights
The most consequential psychedelic therapy conversation of 2026 is not about psilocybin or ketamine , it is about ibogaine, a Schedule I substance derived from the African iboga plant that is attracting serious federal attention for its potential to treat opioid use disorder (OUD). As the FDA naviga
Embed this episode
NOW PLAYING
What Healthcare Marketers Need to Know About Ibogaine's Clinical Promise and Regulatory Path
0:00
16:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 1nessAgency Insights?
This episode is 16 minutes long.
When was this 1nessAgency Insights episode published?
This episode was published on April 22, 2026.
Can I download this 1nessAgency Insights episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!